NasdaqCM - Delayed Quote USD

Eyenovia, Inc. (EYEN)

Compare
0.4866 -0.0136 (-2.72%)
At close: November 7 at 4:00 PM EST
0.4900 +0.00 (+0.70%)
After hours: November 7 at 5:15 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Michael M. Rowe CEO, President & Director 775.47k -- 1962
Dr. Tsontcho Ianchulev M.D., M.P.H., MPH Co-Founder & Executive Director 167.5k -- 1974
Mr. Bren Kern COO & Corporate VP 415.58k -- 1981
Mr. John P. Gandolfo CPA Secretary 578.15k -- 1961
Mr. Andrew D. Jones CFO, Secretary & Treasurer -- -- 1971
Mr. Tony Cardinale Vice President of Sales -- -- --
Mr. Norbert Lowe Senior Vice President of Commercial Operations -- -- --
Alexander Lobo Investor Contact -- -- --

Eyenovia, Inc.

295 Madison Avenue
Suite 2400
New York, NY 10017
United States
833 393 6684 https://www.eyenovia.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
57

Description

Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company has agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Corporate Governance

Eyenovia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 12, 2024 at 9:00 PM UTC

Eyenovia, Inc. Earnings Date

Recent Events

October 4, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

October 1, 2024 at 12:00 AM UTC

S-3: Offering Registrations

September 20, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 3, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 23, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 22, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 14, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 12, 2024 at 8:30 PM UTC

Q2 2024 Earnings Call

July 29, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers